As CGRP-targeted therapies move into wider use, new data are beginning to clarify their role in special populations, the value of switching agents when one fails, and their long-term vascular safety.

Levels of immune responses in tertiary lymphoid structures of non-small cell lung cancer (NSCLC) and association with survival. Predication of clinical outcomes of advanced cutaneous squamous cell ...